// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Maximum human objectively measured pilocarpine stimulated accommodative amplitude

A. Grzybowski - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Phenylephrine

CXL and visual rehabilitation in keratoconus: myths and reality

S. Hamada - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Keratoconus

N/A

Endophthalmitis rate following intravitreal injection of anti‐VEGF and the impact of post‐injection topical antibiotics

F. Horner - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Is bigger better? Glistenings, forward light scatter and visual performance

C. Hull - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Just how broken are we? Neck and back pathology among ophthalmologists

G. Hunter - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Diagnostic accuracy of a new thresholding glaucoma screening programme using temporally modulated flicker

A. Jindal - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Glaucoma

N/A

Neurodegeneration in the brain – before or after the retina?

J. Jolly - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Leber congenital amaurosis

Regain

Gonococcus: a rare cause of infective conjunctivitis

R. Jones - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Three year real‐life outcomes from the use of the fluocinolone acetonide implant (Iluvien) in the treatment of refractory DMO

E. Karatsai - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fluocinolone Acetonide

Intravitreal rituximab for the treatment of ocular lymphoma and glaucoma

A. Lockwood - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Glaucoma

Rituximab

The effects of corneal collagen cross‐linking and the discrepancy between epithelium on and epithelium off treatment – Results from the Portsmouth population cohort

C. Macgregor - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ribo-100

Glaucoma drainage devices: making surgery simpler

R. Manns - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Glaucoma

Fluorescein sodium

Innovation and advances in bioelectronic medicine progressing to address atrophic dry AMD with wireless sub‐retinal photovoltaic implant

M. Muqit - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Retinitis pigmentosa

Methadone hydrochloride

Refractive error and forward light scatter

M. Nagra - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Neuroprotection in glaucoma – outstanding challenges

E.M. Normando - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Glaucoma

N/A

Improving information extraction from visual field data

E.M. Normando - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Glaucoma

N/A

OCT angiography can replace fluorescein angiography in clinical practice ‐ For

V. Papastefanou - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fluorescein sodium

FOXE3 mutations correlations between mutation types, inheritance pattern, and phenotype severity

J. Plaisanci - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Pathogenic variants in the X‐linked BCOR gene cause two different syndromes

N. Ragge - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cortical anomalies in response to RGC damage: how do they affect the visual field and how should we measure them?

T. Redmond - European Association for Vision and Eye Research (EVER) , 2018

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Glaucoma

N/A

Copyright © 2026. QuantiNova All rights reserved